ReviewGlobal health & medicine2026
Artificial intelligence (AI)-aided clinical data management: Applications, human-in-the-loop workflows, and regulatory considerations.
Review in Global health & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical data management (CDM) is central to the quality of clinical research. In Japan, CDM faces a shortage of qualified personnel, particularly in academic research organizations (AROs), as well as increasing data volume and complexity. Rapid advances in artificial intelligence (AI), especially large language models, have therefore attracted attention as a way to support CDM. This review summarizes domestic and international examples of AI utilization in CDM-related tasks, including data cleaning, medical coding, and query generation. Across the cases reviewed, a common implementation principle emerged: a human-in-the-loop design in which AI performs initial processing or detection, while final judgment remains with human personnel. This design is especially relevant to AROs, where high data quality must be maintained with limited CDM human resources. Regulatory frameworks, including ICH E6 (R3) and the FDA-EMA Guiding Principles, are beginning to address AI use, but how AI-aided processes should be handled under Good Clinical Practice remains under discussion. Comprehensive risk mitigation is therefore essential. AI and data are interdependent: better data improve AI performance, and better AI can further improve data quality. The shift from manual processes to human-AI collaborative workflows is likely to accelerate, and CDM must develop the technical, regulatory, and risk-management frameworks needed to support that transition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.